CYTK
Cytokinetics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 3
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
Significant Net Income Decline
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CYTK
Cytokinetics, Incorporated
A late-stage biopharmaceutical company focused on potential treatments for debilitating diseases in which muscle performance is compromised and/or declining
350 Oyster Point Boulevard, South San Francisco, CA 94080
--
Cytokinetics, Incorporated was incorporated on August 5, 1997, under the laws of the State of Delaware. It is a clinical-stage biopharmaceutical company focused on the discovery and development of such a novel small molecule therapeutic approach to modulate muscle function as a potential treatment for critical diseases and poor medical conditions. It is currently in the development stage, focusing on scientific research, development of drug screening technology and financing.
Earnings Call
Q1/2025
Estimate EPS-1.36
Actual EPS-1.36
Estimate Revenue2.61M
Actual Revenue1.60M
Cytokinetics' Q1 2025 Earnings: Unpacking Regulatory Contradictions on REMS, ACACIA, and MAPLE Data Strategy
May 07,2025 07:28
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CYTK has released its 2025 Q3 earnings. EPS was reported at -2.55, versus the expected -1.57, missing expectations. The chart below visualizes how CYTK has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CYTK has released its 2025 Q3 earnings report, with revenue of 1.94M, reflecting a YoY change of 318.14%, and net profit of -306.18M, showing a YoY change of -90.71%. The Sankey diagram below clearly presents CYTK's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
